MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer

Department of Surgery, Clinical Science Institute, University Hospital/National University of Ireland Galway, Galway, Ireland.
Breast cancer research: BCR (Impact Factor: 5.88). 06/2009; 11(3):R27. DOI: 10.1186/bcr2257
Source: PubMed

ABSTRACT Breast cancer is a heterogeneous disease encompassing a number of phenotypically diverse tumours. Expression levels of the oestrogen, progesterone and HER2/neu receptors which characterize clinically distinct breast tumours have been shown to change during disease progression and in response to systemic therapies. Mi(cro)RNAs play critical roles in diverse biological processes and are aberrantly expressed in several human neoplasms including breast cancer, where they function as regulators of tumour behaviour and progression. The aims of this study were to identify miRNA signatures that accurately predict the oestrogen receptor (ER), progesterone receptor (PR) and HER2/neu receptor status of breast cancer patients to provide insight into the regulation of breast cancer phenotypes and progression.
Expression profiling of 453 miRNAs was performed in 29 early-stage breast cancer specimens. miRNA signatures associated with ER, PR and HER2/neu status were generated using artificial neural networks (ANN), and expression of specific miRNAs was validated using RQ-PCR.
Stepwise ANN analysis identified predictive miRNA signatures corresponding with oestrogen (miR-342, miR-299, miR-217, miR-190, miR-135b, miR-218), progesterone (miR-520g, miR-377, miR-527-518a, miR-520f-520c) and HER2/neu (miR-520d, miR-181c, miR-302c, miR-376b, miR-30e) receptor status. MiR-342 and miR-520g expression was further analysed in 95 breast tumours. MiR-342 expression was highest in ER and HER2/neu-positive luminal B tumours and lowest in triple-negative tumours. MiR-520g expression was elevated in ER and PR-negative tumours.
This study demonstrates that ANN analysis reliably identifies biologically relevant miRNAs associated with specific breast cancer phenotypes. The association of specific miRNAs with ER, PR and HER2/neu status indicates a role for these miRNAs in disease classification of breast cancer. Decreased expression of miR-342 in the therapeutically challenging triple-negative breast tumours, increased miR-342 expression in the luminal B tumours, and downregulated miR-520g in ER and PR-positive tumours indicates that not only is dysregulated miRNA expression a marker for poorer prognosis breast cancer, but that it could also present an attractive target for therapeutic intervention.

Download full-text


Available from: Vladimir Benes, Aug 12, 2015
1 Follower
  • Source
    • "Ectopic expression of miR-22E mimics inhibited both 180-and 185-kDa HER-3 at about the same rate, whereas miR-22 reduced the 180-kDa HER-3 first and then the 185-kDa protein at a slower rate. Addition of miR-342 (a miRNA targeting at HER-2), used as a negative control, did not affect expression of HER-3 [39] [40]. (b) Addition of ectopic miR-22 inhibitor (lentimiRa-Off-hsa-miR-22) increased both 180-and 185-kDa HER-3 proteins in H23 and H1437 cells as determined by immunoblotting analysis, confirming our previous results that miR-22 reduced HER-3 protein expressions, and the miR-22 inhibitor reversed the suppressive effect by inhibiting the function of miR-22. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNA-22 (miR-22), a short non-coding RNA that post-transcriptionally regulates mRNA stability and protein synthesis, has been shown to enhance metastatic potential and to suppress HER-3, an important mRNA marker for non-small cell lung cancer (NSCLC). However, the effect of miR-22 has not been investigated in lung adenocarcinoma (LADC), the most common type of NSCLC in the Far East. In this study, we analyzed the role of miR-22 expression in LADC patients. Expression of miR-22 was detected by reverse-transcription polymerase chain reaction (RT-PCR), and confirmed by cDNA sequencing. Signals of miR-22 in LADC sections were identified using in situ hybridization (ISH). The association between miR-22 expression and survival was evaluated by the log-rank test. Induction of miR-22 expression and the effect on HER-3 levels, as well as the subsequent cell behavior were also investigated in vitro. Two types of miR-22: miR-22 and miR-22H, were detected by RT-PCR. The miR-22H had extra 13 bases, 5'-TGTGTTCAGTGGT-3', at the 3'-end, and this segment was named miR-22E. Using ISH, miR-22E overexpression was detected in 225 (83.0%) of 271 LADC patients. A significant difference was found in cumulative survival between patients with high miR-22E levels and those with low miR-22E levels (p < 0.0001). In vitro, epidermal growth factor induced miR-22, but reduced HER-3 expression. Expression of miR-22 increased cell movement ability. In conclusion, expression of miR-22 is closely associated with 363 tumor recurrence, metastasis and overall survival in LADC patients by suppressing HER-3 protein expression to enhance epithelial-mesenchymal transition and metastasis.
    Journal of Cancer Therapy 05/2015; 6(6):362-374. DOI:10.4236/jct.2015.64039
  • Source
    • "miR-206 repressed tumor cell migration through direct targeting of the actin-binding protein Coronin 1C (CORO1C) in TNBC [44]. miR-342 expression was shown to be highest in ER and HER2/neu-positive luminal B tumors and lowest in TNBCs, which could present an attractive target for therapeutic intervention [45]. In addition, the let-7 miRNA family is known to act as tumor suppressors in breast cancer and several let-7 miRNAs may induce tamoxifen sensitivity by downregulation of estrogen receptor α signaling in TNBC cell lines [46]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are small non-coding RNAs that function as major modulators of posttranscriptional protein-coding gene expression in diverse biological processes including cell survival, cell cycle arrest, senescence, autophagy, and differentiation. The control of miRNAs plays an important role in cancer initiation and metastasis. Triple negative breast cancer (TNBC) is a distinct breast cancer subtype, which is defined by the absence of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2/neu). Due to its high recurrence rate and poor prognosis, TNBC represents a challenge for breast cancer therapy. In recent years, a large number of microRNAs have been identified to play a crucial role in TNBC and some of them were found to be correlated with worse prognosis of TNBC. Thus, understanding the novel function of miRNAs may allow us to develop promising therapeutic targets for the treatment of TNBC patients. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Cancer Letters 03/2015; 361(1). DOI:10.1016/j.canlet.2015.02.048 · 5.62 Impact Factor
  • Source
    • "Further, miRNA expression is tissue specific and it has been demonstrated that miRNA expression profiling is more robust in classification of tumours of different origin (Lu et al, 2005). Specifically, in breast cancer, a number of studies defined miRNA expression profiles associated with sporadic breast tumours (Iorio et al, 2005; Volinia et al, 2006, 2012), specific breast cancer subtypes (Blenkiron et al, 2007; Fassan et al, 2009) and tumour biological features such as hormone receptor and HER2 status, metastasis, progression or proliferation (Mattie et al, 2006; Tavazoie et al, 2008; Lowery et al, 2009). There has been longstanding expectation that evolution in molecular profiling may result in pathological classification that more directly reflects the genetic aetiology of non-BRCA1/2 tumours. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Hereditary breast cancer comprises 5–10% of all breast cancers. Mutations in two high-risk susceptibility genes, BRCA1 and BRCA2, along with rare intermediate-risk genes and common low-penetrance alleles identified, altogether explain no more than 45% of the high-risk breast cancer families, although the majority of cases are unaccounted for and are designated as BRCAX tumours. Micro RNAs have called great attention for classification of different cancer types and have been implicated in a range of important biological processes and are deregulated in cancer pathogenesis. Methods: Here we have performed an exploratory hypothesis-generating study of miRNA expression profiles in a large series of 66 primary hereditary breast tumours by microarray analysis. Results: Unsupervised clustering analysis of miRNA molecular profiles revealed distinct subgroups of BRCAX tumours, ‘normal-like' BRCAX-A, ‘proliferative' BRCAX-B, ‘BRCA1/2-like' BRCAX-C and ‘undefined' BRCAX-D subgroup. These findings introduce a new insight in the biology of hereditary breast cancer, defining specific BRCAX subgroups, which could help in the search for novel susceptibility pathways in hereditary breast cancer. Conclusion: Our data demonstrate that BRCAX hereditary breast tumours can be sub-classified into four previously unknown homogenous groups characterised by specific miRNA expression signatures and histopathological features.
    British Journal of Cancer 10/2013; 109(10). DOI:10.1038/bjc.2013.612 · 4.82 Impact Factor
Show more